Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose
Immune responses remained high for MenA/C/W/Y and above baseline for MenB through 4 years after the MenABCWY primary series, with robust responses for all 5 serogroups observed following a booster. The MenABCWY booster had an acceptable safety and tolerability profile consistent with the primary series. NCT03135834.
Authors
- Daniel Dražan
- Annaliesa S. Anderson (ORCID: https://orcid.org/0000-0002-6413-1718)
- Johannes Beeslaar (ORCID: https://orcid.org/0000-0003-0454-3515)
- Paula Peyrani (ORCID: https://orcid.org/0000-0001-8958-1734)
- Jason D. Maguire
- Roger Maansson
- James T. Peterson
- Luis Jódar (ORCID: https://orcid.org/0000-0003-1246-530X)
- William C. Gruber (ORCID: https://orcid.org/0000-0002-6518-4547)
- Robert O’Neill
- Beth Moughan
- Lefteris Zolotas
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Allergan (United Kingdom) (GB)
- Jean Brown Research (US)
- Nemocnice Jindřichův Hradec (CZ)
Publication Details
- Journal
- Vaccine
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126469
- Citations
- 3
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 1.03
Funders
- Pfizer